All In Biotech

Drug Trial Radar · NCT06586294

A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

A Phase Ib/II Open Label,Dose Escalation and Dose Extension Study Evaluating the Safety, Tolerability, and Initial Antitumor Efficacy of Anti-PD-1 and Lymphocyte Activation Gene 3(LAG-3) Bispecific Antibody AK129 Combined With Chemotherapy With or Without Cadonilimab in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Negative Unresectable Locally Advanced or Metastatic G/GEJ Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Sep 30, 2024

Primary completion

Apr 20, 2026

Study completion Apr 20, 2026

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase Ib/II clinical study of AK129 combined with chemotherapy with or without cadonilimab in first-line treatment of advanced HER2 negative gastric cancer or gastroesophageal junction adenocarcinoma

Conditions

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma

Interventions

  • Drug: AK129 Drug:oxaliplatin Drug:capecitabineDrug

    The study drug will be administered at the specified dose and frequency.

  • Drug: AK129 Drug: cadonilimab Drug: oxaliplatin Drug: capecitabineDrug

    The study drug will be administered at the specified dose and frequency.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events(AE)Time frame: Up to approximately 2 years
  2. Incidence of serious adverse events(SAE) and suspected unexpected serious adverse reactions(SUSAR)Time frame: Up to approximately 2 years
  3. Incidence of dose-limiting toxicity(DLT)Time frame: Up to approximately 2 years
  4. Clinically significant changes in safety/laboratory evaluation parameters and AEs that led to treatment termination or suspensionTime frame: Up to approximately 2 years
  5. Objective Solution Rate (ORR) based on RECIST v1.1Time frame: Up to approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Cancer Hospital

    Hanzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.